Mindy Simpson to Recombinant Proteins
This is a "connection" page, showing publications Mindy Simpson has written about Recombinant Proteins.
Connection Strength
0.653
-
Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products. J Manag Care Spec Pharm. 2020 Apr; 26(4):504-512.
Score: 0.166
-
Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors. Haemophilia. 2017 Nov; 23(6):844-851.
Score: 0.142
-
PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding. Haemophilia. 2017 Nov; 23(6):832-843.
Score: 0.140
-
Management of joint bleeding in hemophilia. Expert Rev Hematol. 2012 Aug; 5(4):459-68.
Score: 0.099
-
Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis. J Thromb Haemost. 2018 01; 16(1):39-43.
Score: 0.071
-
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors. Cochrane Database Syst Rev. 2017 09 25; 9:CD011441.
Score: 0.035